

DATA SHEET
Hsa-miR-200bProbe

Catalog No.	Description
HM200B-100	One vial of 0.650 ml of probe in hybridization buffer

Analyte Specific Reagent. Analytical and performance characteristics are not established.

Doc. No. 932-HM200B-100 Rev : D
Date of release: 14-Aug-2020

Description

The Hsa-miR-200bprobe has been designed from mature human miR-200b sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *in-Situ* hybridization.

Specifications

The Hsa-miR-200b identifies mature miR-200b sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in-situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

Storage and Handling

Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

Precautions:

For professional use, the probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

Quality Control

Each lot of this micro RNA probe is tested by *In Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

References

1. Lorio MV and Croce CM. (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. **EMBO Mol Med** 4, 143–159.
2. Chen PS, Su JL, and Hung MC. (2012). Dysregulation of Micro RNAs in cancer. **Journal of Biomedical Science**, 19:90.
3. Nuovo GJ. (2008). In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. **Methods** 44,39–46.
4. Song R. et al. (2010). *In situ* hybridization detection of microRNAs. **Methods Mol Biol.** 629, 287-94.
5. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and
6. Iliopoulos D, Lindahl-Allen M, Polytaichou C, Hirsch HA, Tschlis PN, Struhl K. Loss of miR-200

BioGenex

48810 Kato Road, Suite 100E & 200E
Fremont, CA 94538
Tel : +1 (800) 421-4149, Fax: +1 (510) 824-1490,
support@biogenex.com

inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. *Mol Cell* 2010; 39:761-72

7. Chan YC, Khanna S, Roy S, Sen CK. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. *J BiolChem* 2011; 286:2047-56
8. Chan YC, Roy S, Khanna S, Sen CK. Downregulation of endothelial microRNA-200b supports cutaneous wound angiogenesis by desilencing GATA binding protein 2 and vascular endothelial growth factor receptor 2. *ArteriosclerThrombVascBiol* 2012; 32:1372-82
9. Kawamura T, Ono K, Morimoto T, Wada H, Hirai M, Hidaka K, et al. Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes. *J BiolChem* 2005; 280:19682-8

BioGenex Quality Control Testing Conditions

Parameter	Conditions used
Control Tissue	TCC, PROSTATE (FB-HM200B).
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues